Avadel Pharmaceuticals plc Stock price

Equities

AVDL

US05337M1045

Pharmaceuticals

Market Closed - Nasdaq 04:00:00 2023-12-05 pm EST Intraday chart for Avadel Pharmaceuticals plc 5-day change 1st Jan Change
13.75 USD +4.88% +19.77% +92.04%
Sales 2023 * 24.36M Sales 2024 * 142M Capitalization 1.23B
Net income 2023 * -160M Net income 2024 * -40M EV / Sales 2023 *
50,7x
Net cash position 2023 * - Net cash position 2024 * - EV / Sales 2024 *
8,72x
P/E ratio 2023 *
-6,85x
P/E ratio 2024 *
-30,6x
Employees 41
Yield 2023 *
-
Yield 2024 *
-
Free-Float 39.69%
More Fundamentals * Assessed data
Dynamic Chart
European Equities Traded in the US as American Depositary Receipts Trend Slightly Higher Wednesday MT
European Equities Traded in the US as American Depositary Receipts Ease to Start Week MT
European Equities Traded in the US as American Depositary Receipts Climb Higher Friday MT
European Equities Traded in the US as American Depositary Receipts Rise Sharply Friday, Up 2.7% for Week MT
European Equities Traded in the US as American Depositary Receipts Open Week Lower in Monday Trading MT
European Equities Traded in the US as American Depositary Receipts Trend Lower Friday MT
Oil Stocks Buoy European Equities Traded in the US as American Depositary Receipts Thursday MT
Avadel Pharmaceuticals Shares Jump After Q3 Revenue Beat MT
European Equities Traded in the US as American Depositary Receipts Edge Higher in Wednesday Trading MT
Transcript : Avadel Pharmaceuticals plc, Q3 2023 Earnings Call, Nov 08, 2023 CI
Avadel Pharmaceuticals plc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading MT
European Equities Traded in the US as American Depositary Receipts End Rough Week Lower Friday MT
Avadel Pharmaceuticals Says Results Support Clinical Benefit of Narcolepsy Drug Lumryz MT
Avadel Pharmaceuticals Announces Data Supporting Clinical Profile for Lumryz (Sodium Oxybate) for Extended-Release Oral Suspension At World Sleep 2023 CI
More news
1 day+4.88%
1 week+19.77%
Current month+19.15%
1 month+26.38%
3 months+7.30%
6 months-4.51%
Current year+92.04%
More quotes
1 week
11.36
Extreme 11.36
13.93
1 month
10.25
Extreme 10.25
13.93
Current year
6.35
Extreme 6.35
16.85
1 year
5.92
Extreme 5.92
16.85
3 years
1.05
Extreme 1.05
16.85
5 years
1.03
Extreme 1.03
16.85
10 years
1.03
Extreme 1.03
26.09
More quotes
Managers TitleAgeSince
Chief Executive Officer 56 2017
Director of Finance/CFO 58 2019
Chief Operating Officer - 2014
Members of the board TitleAgeSince
Director/Board Member 54 2018
Chief Executive Officer 56 2017
Director/Board Member 71 2019
More insiders
Date Price Change Volume
23-12-05 13.75 +4.88% 1,368,893
23-12-04 13.11 +4.63% 881,320
23-12-01 12.53 +8.58% 808,127
23-11-30 11.54 +1.14% 291,772
23-11-29 11.41 -0.61% 230,301

Delayed Quote Nasdaq, December 05, 2023 at 04:00 pm EST

More quotes
Avadel Pharmaceuticals PLC is a biopharmaceutical company. The Company's lead product, LUMRYZ, is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. Its approach includes applying solutions to the development of medications that address the patients face with treatment options. Its drug delivery technologies include MICROPUMP, LIQUITIME and MEDUSA. Its MICROPUMP technology allows for the development of modified release solid, oral dosage formulations of drugs. Its LIQUITIME technology allows for the development of modified release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its MEDUSA technology allows for the development of modified-release injectable dosage formulations of drugs.
More about the company
Trading Rating :
Investor Rating :
ESG Refinitiv :
-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
13.75USD
Average target price
20USD
Spread / Average Target
+45.45%
Consensus
1st Jan change Capi.
+92.04% 1 235 M $
+60.77% 529 B $
+46.50% 444 B $
-10.25% 382 B $
-4.25% 269 B $
-10.54% 255 B $
-13.61% 231 B $
+1.76% 200 B $
-9.57% 198 B $
-43.23% 164 B $
Other Pharmaceuticals
  1. Stock
  2. Equities
  3. Stock Avadel Pharmaceuticals plc - Nasdaq
Secure and Increase the Performance of your Investments with our Team of Experts at your Side
Securing my Investments
fermer